Screening Young Adults for Loneliness: What the Trials Actually Cover

The recommendation now circulating through primary care and college health guidance is straightforward: ask patients about loneliness and social isolation routinely, not just when a patient volunteers it. The U.S. Surgeon General’s 2023 advisory framed social disconnection as a population-wide health risk and called for connection to be built into clinical practice generally, not confined to geriatric medicine. Campus health services and some primary care systems have started extending that logic to young adults, a population that multiple surveys place at the top of the loneliness distribution. The 2021 Harvard Making Caring Common survey found 61% of adults aged 18-25 reporting serious loneliness, the highest of any age group it measured. The 2025 Cigna Group survey found Gen Z and Millennial respondents reporting more loneliness than Gen X or Baby Boomers, despite greater digital connectivity.

The prevalence case for paying attention to this age group is not in serious dispute. The evidentiary question is different: what is the quality of evidence that routine clinical screening, specifically, improves outcomes for young adults? Here the record is thinner than the confidence of the recommendation suggests.

Where the screening recommendation actually comes from

The foundational document for routine assessment is the National Academies’ 2020 consensus report, which concluded that roughly a quarter of adults 65 and older are socially isolated and called on the health care system to assess isolation and loneliness routinely. That is an older-adult report, built on an older-adult evidence base, and it says so. The clinician-facing commentary published later that year in the American Journal of Geriatric Psychiatry argued for embedding routine assessment into practice, again explicitly in the context of geriatric care and what that would require of clinicians serving that population.

The Surgeon General’s advisory broadened the frame considerably, treating loneliness as comparable in mortality risk to smoking up to 15 cigarettes a day and calling for a six-pillar national strategy that spans age groups. That is a policy document making a population-health argument, not a clinical trial establishing that screening young adults specifically changes anything for them. The extension of the National Academies’ older-adult recommendation to young-adult settings is an analogical leap, not a tested one.

The trials that exist are in the wrong population

Two of the more rigorous intervention studies available in this literature are the HEAL-HOA randomized controlled trial, published in The Lancet Healthy Longevity in 2024, and the 2025 befriending randomized trial published in Clinical Gerontologist. Both are genuine advances for the field: randomized controlled trials of loneliness interventions are rare, and most of the intervention literature consists of small uncontrolled programme evaluations. HEAL-HOA tested prosocial engagement and volunteering against a control condition among lonely older adults in Hong Kong. The befriending trial, conducted in residential aged care, found reductions of 2.39 points on the UCLA Loneliness Scale at eight weeks and 2.71 points at sixteen weeks relative to control.

Neither trial enrolled young adults. Neither was designed to test what happens when a clinician flags loneliness during a routine visit and refers a patient in their twenties to some pathway of care. The best available randomized evidence on what to do about loneliness, once identified, comes from a population and a care setting entirely different from the one the screening recommendation is now being applied to.

Social prescribing research, which sits closest to the “screen and refer” model in practice, has the same problem in the other direction: it lacks trial rigor generally. A 2022 qualitative meta-synthesis in BMC Health Services Research found that participants across studies described benefits extending beyond social contact to restored purpose, but the review was built on qualitative accounts, not randomized outcomes. A 2025 systematic review protocol focused on older adults noted that only one peer-reviewed randomized controlled trial exists in that specific area, despite growing adoption of social prescribing programmes. If the trial evidence for social prescribing is thin even in the older-adult population where most of the programme activity has occurred, it is close to absent for young adults.

The one study in this list that actually examines young adults, the 2025 Frontiers in Psychology paper on college students coming out of the pandemic, is observational. It found that certain kinds of social connection predicted wellbeing better than others among college students, which is a useful finding about what kind of contact matters. It does not test whether a screening question in a health visit, followed by some intervention, changes loneliness or downstream health outcomes in that population.

Isolation and loneliness are not being separated in the recommendation

A second problem sits underneath the trial gap. The National Academies report and most of the clinical guidance built on it treat isolation and loneliness as a single construct to be screened for with one question or one short instrument. The 2024 study in Scientific Reports on isolation and age during the COVID-19 pandemic found that the relationship between the two varies by age group, which argues against a single screening approach applied uniformly across the lifespan. A structurally isolated young adult living alone in a new city and a lonely young adult embedded in a large but unsatisfying social network are different clinical problems, and a single screening item will not distinguish them. Neither the National Academies report nor the Surgeon General’s advisory specifies which construct a young-adult screening protocol should target, or with which instrument.

Instrument comparability is a live issue even in prevalence measurement, let alone screening. The 2025 HINTS-6 analysis found roughly 1 in 7 U.S. adults reporting severe loneliness and over 37% reporting moderate-to-severe loneliness, using 2022 survey data published three years later. That figure sits awkwardly next to the Harvard MCC survey’s 61% figure for young adults and the Cigna survey’s 57% overall figure, because the three used different instruments and different reference periods. A clinical screening tool inherits this same measurement instability, and none of the guidance documents driving the young-adult screening recommendation has settled on a validated, age-appropriate instrument.

What the recommendation would need to earn its confidence

A defensible clinical recommendation for young adults would require, at minimum, a randomized trial that enrolls young adults specifically, tests a screening protocol against usual care, uses a validated instrument capable of distinguishing isolation from loneliness, and follows patients long enough to observe whether identification changes anything downstream — health care utilization, symptom burden, or loneliness scores themselves. Nothing in the current literature does this. What exists is a strong prevalence case, a plausible mortality-risk case built mostly on older and mixed-age cohorts, and an intervention evidence base generated almost entirely outside the population the recommendation now targets. The recommendation to screen young adults may turn out to be sound. It is not yet evidence-based in the specific sense that matters to a clinician deciding whether to add another question to an already crowded intake form.